The Inflation Reduction Act: Understanding the Impact on Biologic Innovation and the Biosimilar Marketplace
Ali I. Ahmed
Senior Vice President, Biosimilars
Fresenius Kabi USA, LLC
Alice Chen
Associate Professor of Public Policy, Vice Dean for Research
USC Sol Price School of Public Policy
Pavi Kullar
Pharmacy Purchasing Manager
Boston Medical Center
Kelly Goldberg
Vice President, Law and Senior Counsel for Biopharmaceutical Regulation
PhRMA
Anna K. Abram
Senior Advisor
Akin Gump Strauss Hauer & Feld LLP
- Understanding how the IRA is affecting innovation, R&D, and economics in the biologic and biosimilars marketplaces
- Assessing how the IRA’s changes to reimbursement for these products under Medicare Parts B and D may lead to legal challenges and economic uncertainties
- Reviewing the CMS proposed timeline for inflation rebates on biologic-biosimilar products
- Analyzing the competition between new biologics and biosimilar drugs in the commercial marketplace outside of government payor programs
- Devising best practices to assess the commercial viability of your biopharmaceutical portfolio in this new political and economic atmosphere